| P/E (FY) | — | Sales (TTM) | $76.4M |
| Earnings (TTM) | $15.3M | ROE | −14.44% |
| Net Margin | −12.52% | ROIC | −15.25% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 3.45% |
| Market Cap | $187.7M | Trading Days | 5311 |
| 52W High | 3.19 |
| 52W Low | 1.41 |
| % Off High | −26.96% |
| YTD | 29.44% | 1Y | 55.33% |
| 3Y | 40.36% | 5Y | 43.83% |
| 10Y | −64.05% | Since incept. (ann.) | −9.67% |
Single Operating 100%
| Ann. Volatility (1Y) | 64.26% | Ann. Volatility (3Y) | 67.46% |
| Sharpe (1Y) | 1.03 | Sharpe (3Y) | 0.52 |
| Max Drawdown (1Y) | −39.68% | Max Drawdown (3Y) | −56.03% |
| Beta (3Y, vs SPY) | 0.12 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRIS | CURIS INC | $188.3M | — |
| DTIL | PRECISION BIOSCIENCES INC | $185.0M | — |
| LENZ | LENZ Therapeutics, Inc. | $184.4M | — |
| VYGR | Voyager Therapeutics, Inc. | $183.7M | — |
| ACOG | Alpha Cognition Inc. | $183.1M | — |
| ALGS | Aligos Therapeutics, Inc. | $181.1M | — |
| BCDA | BioCardia, Inc. | $180.0M | — |
| IVVD | Invivyd, Inc. | $174.8M | — |
| BCAB | BioAtla, Inc. | $207.7M | — |
| ALEC | Alector, Inc. | $168.8M | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M | — |
| TARA | Protara Therapeutics, Inc. | $214.7M | — |
